Physician profile
Honey East
NPI 1932132495
$721,113.25
in general payments reported to CMS, 2019-2025
63 companies · $101K in 2025
The $101K reported for 2025 was more than what 98% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $190K · 2020: $113K · 2021: $51K · 2022: $87K · 2023: $95K · 2024: $86K · 2025: $101K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $209K · Travel and Lodging: $32K · Honoraria: $16K · Food and Beverage: $14K · Consulting Fee: $9,330 · Education: $138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $209,428.00 |
| Travel and Lodging | $31,895.14 |
| Honoraria | $16,291.75 |
| Food and Beverage | $13,951.61 |
| Consulting Fee | $9,330.00 |
| Education | $137.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $319,303.07 | 2019-2025 | Korlym |
| Amgen INC. | $163,466.76 | 2019-2025 | Repatha, Evenity, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $132,782.75 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Lilly USA, LLC | $88,863.81 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Biomarin Pharmaceutical INC. | $2,457.00 | 2022 | |
| Novo Nordisk INC | $2,266.22 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $1,417.75 | 2019-2025 | Ubrelvy, Synthroid |
| Abbott Laboratories | $1,382.57 | 2020-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $1,170.45 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $540.72 | 2019-2025 | |
| Medtronic, INC. | $493.26 | 2021-2025 | Minimed 780g |
| Dexcom, INC. | $481.35 | 2021-2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $452.73 | 2022-2025 | |
| Amneal Pharmaceuticals LLC | $423.22 | 2020-2025 | Unithroid |
| Insulet Corporation | $393.66 | 2019-2025 | Omnipod |
Show all 63 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $388.67 | 2019-2025 | Evkeeza |
| Bayer Healthcare Pharmaceuticals INC. | $351.80 | 2021-2025 | |
| Amarin Pharma, INC. | $348.26 | 2019-2022 | |
| Esperion Therapeutics, INC. | $285.77 | 2020-2025 | Nexletol, Nexlizet |
| Tandem Diabetes Care, INC. | $277.74 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Merck Sharp & Dohme LLC | $236.17 | 2019-2021 | |
| Radius Health, INC. | $224.98 | 2019-2025 | |
| Recordati_rare_diseases_inc. | $218.70 | 2021-2025 | Isturisa, Signifor Lar |
| Pfizer INC. | $218.50 | 2020-2024 | |
| Grt US Holding, INC. | $203.36 | 2021-2022 | |
| Averitas Pharma INC. | $179.50 | 2023-2025 | Qutenza |
| Regeneron Pharmaceuticals, INC. | $163.82 | 2025 | Evkeeza |
| Ascendis Pharma Endocrinology INC | $153.99 | 2025 | Yorvipath |
| Axsome Therapeutics, INC. | $152.06 | 2025 | Auvelity, Sunosi |
| Xeris Pharmaceuticals, INC. | $151.75 | 2022-2025 | Recorlev, Gvoke Hypopen |
| Alexion Pharmaceuticals, INC. | $133.43 | 2019-2025 | Strensiq |
| Rhythm Pharmaceuticals, INC. | $124.79 | 2022-2024 | Imcivree |
| Chiesi USA, INC. | $106.68 | 2024-2025 | Mycapssa |
| Neurocrine Biosciences, INC. | $106.24 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $105.43 | 2019-2020 | |
| Acella Pharmaceuticals, LLC | $74.75 | 2024-2025 | NP Thyroid 60 |
| Horizon Therapeutics Plc | $74.42 | 2022-2023 | Tepezza |
| Kowa Pharmaceuticals America, INC. | $70.70 | 2021 | |
| Tolmar, INC. | $64.48 | 2024-2025 | Jatenzo |
| Ionis Pharmaceuticals, INC. | $62.00 | 2025 | Tryngolza |
| Ibsa Pharma INC. | $57.42 | 2021-2023 | Tirosint, Licart |
| Ultragenyx Pharmaceutical INC. | $55.16 | 2020-2022 | |
| Rgh Enterprises LLC | $48.68 | 2025 | |
| Currax Pharmaceuticals LLC | $47.68 | 2022-2024 | Contrave, Nexlizet, Nexletol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.52 | 2019-2022 | |
| Lifescan, INC. | $45.89 | 2021-2022 | |
| Shire North American Group INC | $43.58 | 2019 | |
| Eusa Pharma (US) LLC | $42.71 | 2022 | |
| Amryt Pharma Holdings LTD | $42.51 | 2023 | Mycapssa |
| Sequel Med Tech, LLC | $39.45 | 2025 | Twiist |
| Ascensia Diabetes Care US INC. | $33.05 | 2021-2025 | |
| Beta Bionics, INC. | $31.38 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Nalpropion Pharmaceuticals LLC | $26.86 | 2019 | |
| Aegerion Pharmaceuticals, INC. | $26.71 | 2019 | |
| Stryker Corporation | $23.75 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Embecta Corp. | $22.53 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Valeritas, INC. | $18.65 | 2019 | |
| Travere Therapeutics, INC. | $17.34 | 2019 | |
| Becton, Dickinson and Company | $16.60 | 2020 | |
| Antares Pharma, INC. | $15.26 | 2025 | Xyosted |
| Senseonics, Incorporated | $14.00 | 2019 | |
| Acerus Pharmaceuticals Corporation | $12.70 | 2022 | |
| Medtronic Minimed, INC. | $11.51 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Honey East listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.